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The availability of adult malignant glioma stem cells
(GSCs) has provided unprecedented opportunities
to identify the mechanisms underlying treatment
resistance. Unfortunately, there is a lack of compara-
ble reagents for the study of pediatric low-grade gli-
oma (LGG). Leveraging a neurofibromatosis 1 (Nf1)
genetically engineered mouse LGGmodel, we report
the isolation of CD133+ multi-potent low-grade gli-
oma stem cells (LG-GSCs), which generate glioma-
like lesions histologically similar to the parent tumor
following injection into immunocompetent hosts.
In addition, we demonstrate that these LG-GSCs
harbor selective resistance to currently employed
conventional and biologically targeted anti-cancer
agents, which reflect the acquisition of new target-
able signaling pathway abnormalities. Using tran-
scriptomic analysis to identify additional molecular
properties, we discovered that mouse and human
LG-GSCs harbor high levels of Abcg1 expression
critical for protecting against ER-stress-induced
mouse LG-GSC apoptosis. Collectively, these find-
ings establish that LGG cancer stem cells have
unique molecular and functional properties relevant
to brain cancer treatment.INTRODUCTION
Numerous cancers are maintained by small populations of cells
with stem-cell-like properties (Hope et al., 2004; Kim et al., 2005;
Ricci-Vitiani et al., 2007), including those of the nervous system
(Singh et al., 2004). These stem cells have the capacity for self-
perpetuation aswell as to generatemature cells of specific tissue
lineages (Bonnet and Dick, 1997; Kim et al., 2005; Singh et al.,
2003; Vermeulen et al., 2008) and, in this respect, represent
good candidates for therapeutic intervention. The importance
of this population to brain tumor biology is underscored by the
demonstration that cancer stem cells (CSCs) generate tumors
following injection into immunocompromised mice with similarCellhistologic and growth properties to the parental tumor (Galli
et al., 2004; Singh et al., 2004; Taylor et al., 2005). In addition,
these CSCs harbor unique responses to conventional therapeu-
tic agents (Beier et al., 2011; Sakariassen et al., 2007), which
have broad implications for the design of treatments aimed at
eliminating the very cells that maintain and recapitulate the tu-
mor. As such, malignant glioma regrowth following alkylating
agent therapy (temozolomide) in mice is due to the relative resis-
tance of CSCs to this agent (Chen et al., 2012). Moreover, many
of the markers expressed by CSCs also serve as independent
predictors of survival in patients with these malignancies (Hale
et al., 2014; Lathia et al., 2014; Pietras et al., 2014).
In contrast, the study of CSCs in low-grade gliomas (LGGs)
has been hampered by their low clonogenic frequencies (Singh
et al., 2003), technical difficulties inherent in maintaining these
cells in culture (Raabe et al., 2011), and the inability to generate
tumors following xenografting. Complicating the issue in the
context of neurofibromatosis type 1 (NF1), the most common in-
herited disorder in which affected children develop LGG, is the
limited availability of tumor specimens, exquisite brain region
constraints important for tumor initiation and growth (Lee et al.,
2012), and dependence on NF1+/ non-neoplastic immune-
system-like cells (microglia) for glioma formation and mainte-
nance (Daginakatte and Gutmann, 2007; Pong et al., 2013). In
this cancer predisposition syndrome, 15%–20% of children
with NF1 develop World Health Organization (WHO) grade I as-
trocytomas (LGGs) involving the optic nerve and chiasm and,
less commonly, the brainstem (Guillamo et al., 2003). These hu-
man tumors have low proliferative indices (<1%), increased mi-
croglia infiltration, and pleiomorphic neoplastic cells with nuclear
atypia (Louis et al., 2007).
To identify and characterize low-grade glioma stem cells
(LG-GSCs), we leveraged a well-characterized murine model of
NF1-associated low-grade optic glioma (Bajenaru et al., 2003),
in which Nf1+/ mice undergo somatic Nf1 gene inactivation
in neuroglial progenitor cells (Nf1+/GFAPCKO mice). Nearly
100% of Nf1+/GFAPCKO mice develop LGGs of the optic
nerves and chiasm. Similar to their human counterparts, these
tumors likewise have low proliferative indices (<1%), microglial
infiltration, and pleiomorphic neoplastic cells with nuclear atypia
(Bajenaru et al., 2003; Hegedus et al., 2009; Kim et al., 2010). Us-
ing this platform, we isolated CD133+ cells from tumor-bearing,
but not normal, mice that were capable of long-term passage,Reports 10, 1899–1912, March 24, 2015 ª2015 The Authors 1899
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self-renewal, and multi-lineage differentiation as well as the
ability to form glioma-like lesions following transplantation into
naive Nf1+/ immunocompetent animals. Relative to their non-
neoplastic Nf1-deficient neural stem cell counterparts, these
low-grade optic glioma stem cells (o-GSCs) exhibited reduced
sensitivity to some conventional and biologically targeted
agents, which reflected the acquisition of targetable escape
mechanisms. Transcriptomic analyses revealed that o-GSCs ex-
press Abcg1 and Lgr5, which were also found in human low-
grade GSCs. Moreover, we demonstrate that Abcg1 was critical
for maintaining mouse o-GSC survival through suppression of
ER stress. Collectively, this study establishes the existence of
a population of CSCs in mouse LGG with unique functional
and molecular properties.
RESULTS
Nf1+/GFAPCKO Mouse Optic Gliomas Contain CD133+
Stem Cells
To determine whether CSCs could be generated from LGG-
bearing mice, single cells were dissociated from the
optic nerves/chiasm of Nf1flox/flox (wild-type), Nf1+/, and
Nf1+/GFAPCKO mice at 3 months of age and maintained in
defined media. After 1 week culture, neurospheres emerged
from Nf1+/GFAPCKO mouse optic nerve cultures (Figures 1A
and 1B). The frequency of this stem cell population in the
murine optic gliomas ranged from 0.06% to 0.28% (0.15% ±
0.11%; n = 3), determined using a primary sphere-formation
assay (Figure 1A). In contrast, cells from Nf1flox/flox (WT) and
Nf1+/mice took nearly 3 weeks to form smaller clusters, which
could not be maintained by serial passaging due to loss of pro-
liferation and self-renewal ability.
Because these mouse Nf1 optic gliomas (Lee et al., 2012) as
well as some human optic gliomas (Tchoghandjian et al., 2009)
likely arise from third ventricular zone (TVZ) neuroglial progeni-
tors, Nf1-deficient TVZ neural stem cells (NSCs) were employed
as non-neoplastic reference cells (Figure 1C). Both Nf1-deficient
TVZ NSCs and glioma neurospheres expressed Nestin and
Sox2 (Figure 1D) as well as BLBP and Olig2 (Figures S1A
and S1B) but were negative for neurofibromin (Figure 1C) and
GFAP expression (Figure S1A). However, only o-GSCs ex-
pressed CD133 (Figures 1D and 1E), similar to human PA
spheres (Figure S1C). In addition, other GSC markers identified
in glioblastoma GSCs (Lathia et al., 2010; Son et al., 2009;Figure 1. Neurospheres Can Only Be Generated from 3-Month-Old Op
(A) Optic gliomas from 3-month-old Nf1+/GFAPCKO mice have increased optic
the optic nerves and chiasm. Neurospheres were only observed in cultures from
Nf1+/ mice.
(B) After the initial passage, secondary neurospheres formed only in the o-GSC
(C) Loss of neurofibromin expression was observed in o-GSCs and Nf1/ TVZ
(D) Similar to Nf1/ TVZ NSCs, neurospheres from optic gliomas express Nestin
o-GSCs.
(E) Quantitation of cell-type-specific markers.
(F–I) In addition, o-GSCs (passages 8–10) have increased (F) cell numbers and (G)
Nf1/ TVZ NSCs.
(J) Increased glial differentiation was observed in o-GSCs relative to Nf1/ TVZ
mean ± SD.
The scale bars represent 1,000 mm (optic nerve), 100 mm (H&E), and 100 mm (o-G
CellTchoghandjian et al., 2010), including A2B5, CD15, and
CD49f, were expressed in o-GSCs, but not in Nf1/ TVZ
NSCs (Figures 1D and 1E).
o-GSCs could be stably maintained for >30 passages without
significant changes in their growth rates (Figure S1D). Relative
to their non-neoplastic counterparts, o-GSCs had higher fre-
quencies of secondary neurosphere formation (Figure S1E),
increased proliferation (Figures 1F and 1G), decreased cell death
(Figures 1H and 1I), and increased glial differentiation (Figure 1J).
Together, these findings establish the presence of Nf1-deficient
cells with stem cell properties in these low-grade mouse
gliomas.
o-GSCs Induce Glioma-like Lesions In Vivo
To determine whether o-GSCs generate tumors in vivo, we
transplanted 500,000 mCherry-expressing o-GSCs into the
brainstems of 3-week-old Nf1+/mice. Nf1+/mice were cho-
sen to provide a more-faithful genetic background, given that
these tumors arise in patients with a germline NF1 gene muta-
tion. Brainstem injections were performed, as optic nerve injec-
tions are not technically possible, and 15%–20% of NF1-associ-
ated LGGs arise in the brainstem (Guillamo et al., 2003). Within
6 months, all mice transplanted with o-GSCs (n = 11 mice)
harbored areas of increased cellularity consistent with glioma-
like lesions, including abnormal cell clusters (H&E), strong
GFAP immunostaining with elongated cytoplasmic processes
(Figure S2A), and increased microglial (Iba1+ cells) infiltration
relative to the uninjected contralateral sides (Figures 2A and
2B). Similar to optic gliomas arising in Nf1+/GFAPCKO mice,
these ectopic lesions had low proliferative indices (%Ki67+ cells)
and increased percentages of Olig2+ and Iba1+ cells (Figure 2B).
Consistent with the conclusion that these glioma-like lesions
arose from the injected o-GSCs, we found that 66% of the
GFAP+ cells, 62% of the Olig2+ cells, and the majority of the
Ki67+ (72%) were positive for mCherry expression (Figure 2C).
In contrast to o-GSCs, Nf1+/ mice (n = 4) transplanted with
Nf1/ TVZ NSCs did not form glioma-like lesions 6 months
post-injection. Unlike the glioma-like lesions generated following
o-GSC injection, there was only a modest cell accumulation
(H&E) and less-robust GFAP immunostaining but no change
in the percentages of Iba1+ and Olig2+ cells and nearly no prolif-
erating (Ki67+) cells at the injection sites (Figures S2B and S2C).
Importantly, the vast majority of the GFAP+ cells were mCherry-
negative (Figure S2D) with stellate morphologies (Figure S2B,tic Glioma-Bearing Mice
nerve volumes (white arrow) and abnormal cell clusters (white asterisk) within
3-month-old Nf1+/GFAPCKO mice, but not from wild-type (WT), Nf1flox/flox, or
cultures. The scale bar represents 300 mm.
NSCs.
and Sox2. CD133, A2B5, CD15, and CD49f expression were only observed in
percentages of Ki67+ cells, but (H and I) decreased cell apoptosis compared to
NSCs (passage 8). Nuclei were counterstained with DAPI. Values denote the
SCs). *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2. o-GSCs Form Glioma-like Lesions following Injection into Nf1+/ Mice, Similar to the Parent Tumors
(A and B) Abnormal cell clusters, hypercellularity (H&E), increased number of glial fibrillary acidic protein (GFAP)-immunoreactive cells, increased Iba1+ cells
(inset), increased Ki67+ cells (arrows and inset; A), and increased Olig2+ cells (inset) were observed in both the parent optic glioma tumors and ectopic o-GSC
lesions (n = 4 per group). WT optic nerves or the contralateral uninjected sides were used as reference controls.
(C) Immunofluorescence co-labeling shows transgene (mCherry) expression in Ki67-, GFAP-, and Olig2-immunoreactive cells at the injection site.
Error bars denote mean ± SD. The scale bars represent 50 mm (IHC) and 10 mm (IF). *p < 0.05; **p < 0.01.
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Figure 3. o-GSCs Do Not Form Similar Glioma-like Lesions following Injection into Athymic Mice
(A) Only three of the five athymic mice injected with o-GSC showed increased cellularity (H&E) and increased numbers of GFAP-immunoreactive cells.
(B) Whereas increased Iba1+ cells (inset), Ki67+ cells (arrows and inset; A), and Olig2+ cells (inset) were observed at the injection sites relative to contralateral
sides, the percentages of Iba1+ and Ki67+ cells found at the o-GSC injection sites were similar to those on the contralateral (uninjected) sides.
(C) Immunofluorescence co-labeling reveals mCherry expression in Ki67-, GFAP-, and Olig2-immunoreactive cells at the injection site.
Error bars denote mean ± SD. The scale bars represent 50 mm (IHC) and 10 mm (IF). NS, not significant. *p < 0.05.inset), indicating that they were likely host-derived reactive
astrocytes.
To determine whether theNf1+/ local microenvironment was
important for glioma formation, o-GSCs were injected into the
brainstems of immunocompromised athymic mice. In striking
contrast to the glioma-like lesions generated following o-GSC
injection into Nf1+/ mice, immunocompromised mice trans-
planted with o-GSCs did not form gliomas 6 months post-injec-
tion. In total, whereas three of five mice showed hypercellular
lesions with modest GFAP immunostaining and an increasedCellpercentage of Olig2+ cells, no changes in the percentages of
Iba1+ and Ki67+ cells were observed (Figures 3A and 3B).
Despite the absence of a detectable glioma-like lesion in these
mice, there was mCherry expression in the majority of Ki67-,
GFAP-, and Olig2-immunoreactive cells at the injection sites
(Figure 3C). Similarly, there were greater numbers of Iba1+ and
Ki67+ cells at these injection sites (Figure S3); however,
these increases were 2- and 3-fold lower than observed in
Nf1+/ mice, respectively. Together, the development of gli-
oma-like lesions following o-GSC transplantation demonstratesReports 10, 1899–1912, March 24, 2015 ª2015 The Authors 1903
Figure 4. o-GSCs Exhibit Relative Resistance to Carboplatin, Rapamycin, and PD0325901, But Not to Temozolomide and Vincristine,
Treatments
(A and B) Both stem cell populations show similar dose responses to temozolomide and vincristine.
(C–E) o-GSCs exhibit relative resistance to (C) carboplatin, (D) rapamycin, and (E) PD0325901 (PD901) treatment compared to Nf1-deficient TVZ NSCs.
Error bars denote mean ± SD.the gliomagenic nature of these LG-GSCs in concert with the
need for a supportive microenvironment.
o-GSCs Exhibit Selective Resistance to Anti-cancer
Treatments
Emerging evidence supports the concept that high-grade CSCs
may be resistant to therapeutic agents and radiotherapy used
to treat patients with these brain tumors (Bao et al., 2006;
Chen et al., 2012; Liu et al., 2006). To explore the possibility
that o-GSCs might be less sensitive to conventional (Pace
et al., 2003; Packer et al., 1993) or new biologically targeted ther-
apies (rapamycin analogs, NCT01734512 and NCT01158651;
MEK inhibitors, NCT01885195), we exposed Nf1-deficient TVZ
NSCs and o-GSCs to vincristine, temozolomide, carboplatin,
rapamycin (Rap), and the PD0325901 (PD901) MEK inhibitor.
Whereas o-GSCs and Nf1/ TVZ NSCs were equally sensitive
to temozolomide (Figure 4A) and vincristine (Figure 4B), o-GSCs
were more resistant to carboplatin (5-fold increased ED50; Fig-
ure 4C), Rap (6-fold increased ED50; Figure 4D), and PD901 (3-
fold increased ED50; Figure 4E) treatments.
Whereas Rap inhibited mTOR activity in a dose-dependent
fashion, as measured by S6 phosphorylation (Figure S4), the
resistance to Rap was the consequence of increased mTOR
activation in o-GSCs relative to Nf1/ TVZ NSCs (1.5- and
1.7-fold increases S6 Ser240/244 and Ser235/236 phosphorylation,
respectively; Figure 5A). Previous studies in other cell types have
demonstrated that mTOR can be additionally activated by loss of
tuberous sclerosis complex (TSC) function (Kwiatkowski et al.,
2002; Ma et al., 2005; Manning et al., 2002) or p90-RSK-medi-
ated phosphorylation (Carrie`re et al., 2008). Whereas we1904 Cell Reports 10, 1899–1912, March 24, 2015 ª2015 The Authorobserved no change in total tuberin expression, there was
increased hamartin expression in both Nf1/ TVZ NSCs and
o-GSCs and a decrease in phosphorylation-mediated tuberin
inactivation (Ser939 and Thr1462), excluding tuberin/hamartin-
mediated mTOR activation as the mechanism underlying the
increased mTOR activity in o-GSCs (Figure S5A). In contrast,
o-GSCs exhibited increased p90-RSK activation (3-fold increase
in p90-RSK-Thr573 phosphorylation; Figure 5B). To demonstrate
that this acquired p90-RSK hyper-phosphorylation was respon-
sible for the increased mTOR activation in o-GSCs, o-GSCs
were treated with Rap and SL0101 (p90-RSK inhibitor). Con-
sistent with a model in which p90-RSK further activates
mTOR signaling in o-GSCs, SL0101 treatment ameliorated the
observed S6 hyper-phosphorylation and relative resistance to
Rap growth inhibition (Figure 5C).
Whereas the reduced sensitivity to Rap resulted from p90-
RSK-mediated mTOR hyperactivation, o-GSC relative resis-
tance to PD901 treatment was not due to differences in basal
ERK activity (Figure S5B). Moreover, PD901 did not inhibit
ERK-Thr202/Tyr204 phosphorylation as a result of aberrant
MEK activation (phospho-MEK-Ser217/221; Figure 5D). In KRAS
mutant human tumors, reactivation of CRAF creates a MEK-
CRAF complex, which increases MEK/ERK phosphorylation
after PD901 treatment (Lito et al., 2014). Consistent with this
mechanism, PD901 treatment induced MEK binding to CRAF
and resulted in increased CRAF activity (CRAF Ser338 phosphor-
ylation) only in o-GSCs (Figure 5E). To determine whether this
aberrant activation of CRAF was responsible for MEK inhibitor
resistance, o-GSCswere treated with trametinib, aMEK inhibitor
that blocks the association between MEK and CRAF (Lito et al.,s
Figure 5. Mechanisms Underlying the Rela-
tive Resistance of o-GSCs to Rapamycin
and PD0325901 Treatments
(A and B) Increased (A) mTOR activation (S6
phosphorylation) and (B) p90-RSK Thr573 phos-
phorylation were observed in o-GSCs relative to
Nf1/ TVZ NSCs.
(C) Nf1-deficient TVZ NSCs and o-GSCs were
treated with rapamycin (0.5 nM) and SL0101
(50 mM) as indicated. S6 phosphorylation and the
percentage of viable cell number are shown.
(D) PD901 treatment did not inhibit ERK phos-
phorylation due to aberrant MEK activation
(phosphorylation) in o-GSCs.
(E) PD901 treatment induces the formation of
MEK1-CRAF complexes, but increased CRAF
phosphorylation was only observed in o-GSCs.
(F–H) Trametinib (50 nM) reduced (F) CRAF/MEK
binding, (G) MEK/ERK phosphorylation, and (H)
o-GSC growth.
Error bars denote mean ± SD.2014). Trametinib reduced o-GSC MEK/CRAF binding (Fig-
ure 5F), ERK/MEK hyperactivation (Figure 5G), and o-GSC
growth (Figure 5H). Together, these findings reveal new mecha-Cell Reports 10, 1899–1912nisms for o-GSCchemoresistance, which
can be targeted to inhibit the growth of
these CSCs.
o-GSCs Exhibit Increased Abcg1
Expression
In addition to the acquiring escapemech-
anisms to biologically targeted therapies,
we also sought to identify potential mo-
lecular differences between o-GSCs and
their non-neoplastic Nf1-deficient NSC
counterparts. Microarray gene expres-
sion analysis revealed 59 genes with
>5-fold increased expression in o-GSCs
relative to Nf1/ TVZ NSCs (Figure 6A;
Table S1), whereas 87 genes were
decreased by at least 5-fold in o-GSCs
(Table S2). We next prioritized candidate
genes based on their function, including
transcription factors, growth regulators,
cell surface markers, and stem cell
proteins. The majority of candidate tran-
scripts showed subtle increases in
expression (1.3- to 2-fold upregulation)
upon real-time qPCR (data not shown)
validation. However, two transcripts,
Abcg1 and Lgr5, were overexpressed
>3-fold in o-GSCs by qPCR and wes-
tern blotting relative to Nf1-deficient or
Nf1+/ (Figures 6B, 6C, and S6A–S6C)
NSCs from three brain germinal regions
(dentate gyrus, subventricular zone, and
third ventricle). Consistent with these
in vitro results, 20% of the cells in the
intact parental Nf1+/GFAP CKO mouse optic glioma were
Abcg1- or Lgr5-immunoreactive in vivo (Figure 6D). In addition,
ABCG1 and LGR5 were also expressed in human pilocytic, March 24, 2015 ª2015 The Authors 1905
Figure 6. o-GSCs Exhibit Increased Abcg1 Expression
(A) Hierarchical cluster analysis of WT (TVZ_LacZ), Nf1/ (TVZ_Cre) NSCs, and o-GSCs. Three independent arrays representing each sample are shown. The
expression level represents standardized values from 5 (green; <1-fold change) to 5 (red; >1-fold change). No change is denoted by black.
(B and C) Differential expression of two candidate genes, Abcg1 and Lgr5, was validated by (B) qPCR and (C) western blotting.
(D) Increased numbers of Abcg1+ and Lgr5+ cells were found in Nf1 mouse optic gliomas compared to non-tumor-bearing optic nerve sections from WT
(Nf1flox/flox) and Nf1+/ mice (n = 4 per group).
(E) Immunocytochemistry reveals Lgr5 and Abcg1 expression in mouse o-GSCs and spheres from human PAs.
DG, dentate gyrus; SVZ, subventricular zone; TVZ, third ventricle. Error bars denote mean ± SD. Nuclei are counterstained with DAPI. The scale bars represent
100 mm. *p < 0.01; **p < 0.001.
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astrocytomas (PA) spheres generated from two fresh surgical
specimens (Figure 6E). These PA spheres could not be main-
tained beyond two passages, limiting the evaluation of ABCG1
and LGR5 in human LG-GSCs. It is worth noting that no changes
in the expression of other ABC family genes were identified
(Figure S6D), including ABCG2, which defines theGSC side pop-
ulation (Bleau et al., 2009). As such, ABCG2 expression was
detected in humanGBM spheres, but not in either o-GSCs or hu-
man PA spheres (Figure S6E).
Abcg1 Expression Is Critical for Enhanced o-GSC
Survival
Whereas several studies have shown that LGR5 is important for
glioblastoma CSC function and patient survival (Nakata et al.,
2013; Parry and Engh, 2014; Wang et al., 2014), the role of
ABCG1 in glioma pathogenesis is unknown. ABCG1 is a mem-
ber of a large superfamily of membrane-bound ATP-binding
cassette (ABC)-containing proteins important for cellular trans-
port (Tarling and Edwards, 2011; Wang et al., 2004), where it
directs lipid transport (Kennedy et al., 2005; Klucken et al.,
2000). Given the putative role of Abcg1 as a potential unique
glioma stem cell marker, we initially investigated ABCG1
expression in human NF1-associated PA specimens. ABCG1
immunoreactivity was observed in both human NF1-associated
optic pathway (n = 3) and non-optic pathway gliomas (n = 3;
Figure 7A), representing 23%–35% (27% ± 6%) of the total
tumor area similar to that observed in the murine Nf1 optic
gliomas.
Next, we employed shRNA knockdown to define the func-
tional relevance of ABCG1 to o-GSC biology. First, knockdown
of Abcg1 expression using two different lentiviral-mediated
shRNA constructs (Figure 7B; 50%–60% protein reduction)
reduced o-GSC growth and self-renewal by 40%–46% (Fig-
ure 7C) and 76%–78% (Figure 7D), respectively. This decrease
in cell number was not the result of reduced proliferation (Fig-
ure 7E) but rather reflected a 2-fold increase in apoptosis
(Figure 7F).
Second, to determine whether caspase activation (cleavage)
was induced in Abcg1 knockdown-induced apoptosis, caspase
pathway activation in o-GSCs following shAbcg1 silencing was
examined. Cleavage of one initiator caspase (caspase-12, but
not caspase-9) as well as the caspase-6, caspase-3, and poly
(ADP-ribose) polymerase (PARP) downstream effectors was
observed in o-GSCs after Abcg1 shRNA-mediated knockdown
(Figures 7G and 7H).
Finally, to determine whether ER stress was responsible
for Abcg1 knockdown-induced cell death, the expression of
BiP and CHOP, two markers of ER stress (Liu et al., 1997;
Zinszner et al., 1998), were examined. Abcg1 knockdown
increased BiP and CHOP expression by 2- to 2.5-fold and
4.5- to 7-fold, respectively, relative to controls (Figure 7I).
Tunicamycin was included as a positive control for ER stress
induction. Moreover, BiP, CHOP, cleaved caspase-3, and
cleaved PARP expression in Abcg1 knockdown o-GSCs
were reduced to control levels (Figure 7J) following 4-phenyl
butyric acid (PBA) treatment, a treatment capable of blocking
ER stress (Erbay et al., 2009; Ozcan et al., 2006). Together,
these results demonstrate that Abcg1 provides a survivalCelladvantage to o-GSCs by suppressing ER stress induction
(Figure 7K).
DISCUSSION
The challenges to studying low-grade GSCs in humans partly
reflect their low-clonogenic frequencies, estimated at 0.3%–
1.5%, relative to high-grade brain tumors (8%–25%) grown
under the same conditions (Singh et al., 2004). In addition, the
failure to generate tumors following human low-grade GSC im-
plantation into immunocompromisedmicemay reflect the exqui-
site brain region specificity and need for a permissive tumor
microenvironment. In this regard, NSCs from different CNS re-
gions exhibit unique molecular signatures (Horiguchi et al.,
2004; Kim et al., 2006) and respond differentially to specific can-
cer-causing genetic changes (Kaul et al., 2012; Lee et al., 2012),
including Nf1 gene inactivation (Lee et al., 2010). Moreover, non-
neoplastic stromal cells (e.g., microglia) are important for both
mouse Nf1 optic glioma development (Pong et al., 2013) and
maintenance (Daginakatte and Gutmann, 2007), such that
disruption of their function delays optic gliomagenesis and re-
duces tumor proliferation.
Based on these considerations, we leveraged a well-charac-
terized murine model of NF1 LGG, in which tumors arise in the
optic nerve. Using this platform, we identified a population of
cells with NSC properties that were additionally capable of form-
ing glioma-like gliomas following transplantation into Nf1+/
mice. Similar to human low-grade GSCs, the clonogenic fre-
quency of o-GSCs in these tumors was less than 1%. In addition,
as observed in human GSCs, o-GSCs expressed the CD133,
A2B5, CD15, and CD49f stem cell markers.
The deployment of this murine LGG system reduced the time
from tumor removal to in vitro expansion, thus facilitating a
detailed examination of the unique molecular and cellular prop-
erties of these low-grade GSCs. First, we demonstrate that
o-GSCs form glioma-like lesions following injection into the
brainstems of Nf1+/mice, a region where gliomas form in chil-
dren with NF1 who harbor a germline NF1 gene mutation. In
striking contrast, Nf1-deficient TVZ NSCs did not generate gli-
omas following transplantation, revealing cellular properties
unique to the o-GSCs not shared with their non-neoplastic
Nf1/ counterparts. The importance of the Nf1+/ supportive
microenvironment was further underscored by a failure to
generate glioma-like lesions following o-GSC injection into the
brainstems of athymic mice.
Second, o-GSCs exhibited a relative selective resistance to
some agents currently used to treat these tumors in children
with NF1. Specifically, carboplatin is often the first-line chemo-
therapy employed for children with NF1-optic glioma (Mahoney
et al., 2000; Packer et al., 1997). The relative resistance to this
agent may explain why some optic gliomas continue to grow
and require alternative second-line therapies. Similarly, recent
clinical trials have employed Rap analogs based on preclinical
evidence demonstrating that Rap suppresses murine Nf1
optic glioma proliferation (Hegedus et al., 2008). In these
murine proof-of-principle studies, 5 mg/kg/day Rap treatment
did not produce a durable response, with tumor regrowth
following the discontinuation of drug, whereas 20 mg/kg/dayReports 10, 1899–1912, March 24, 2015 ª2015 The Authors 1907
Figure 7. Abcg1 Expression Maintains o-GSC Growth
(A) Glioma specimens from six individuals with NF1 exhibit ABCG1 expression relative to age-matched control brains. The scale bar represents 50 mm.
(B) shRNA knockdown of o-GSC Abcg1 expression.
(C and D) shAbcg1 knockdown reduced (C) o-GSC growth and (D) decreased self-renewal. The scale bar represents 200 mm.
(E and F) Following Abcg1 knockdown, there was (E) no change in proliferation (% Ki67+ cells); however, (F) increased apoptosis (% TUNEL+ cells) was observed.
(G and H) Abcg1 knockdown induced caspase-3, caspase-6, caspase-12, and PARP, but not caspase-9, cleavage.
(I) Increased BiP and CHOP expression was observed following Abcg1 knockdown. Tunicamycin (TM) (2 mg/ml) was included as a control to induce ER stress.
(legend continued on next page)
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Rapwas required for continued optic glioma growth suppression
following drug withdrawal. These preclinical observations are
consistent with the reduced Rap sensitivity observed in o-
GSCs and suggest that durable responses may require higher
mTOR inhibitor drug dosing. In this regard, the increased
mTOR activation in o-GSCs was mediated by acquired p90-
RSK hyperactivation, such that the relative Rap resistance could
be ameliorated following combined p90-RSK and mTOR
inhibition.
Previous work has shown that NF1-deficient GBM cells have
variable degrees of MEK inhibitor sensitivity (See et al., 2012).
This relative MEK inhibitor sensitivity was also observed in o-
GSCs, which results from MEK/CRAF binding and CRAF activa-
tion such that treatment with a MEK inhibitor (trametinib) that
additionally promotes the dissociation of MEK from CRAF effec-
tively blocked o-GSC growth. Current preclinical studies are
planned to compare PD901 to trametinib therapy for Nf1murine
optic glioma.
Third, we identified ABCG1 and LGR5 as GSC markers.
Whereas LGR5 has been previously shown to control glioma
proliferation (Parry and Engh, 2014; Wang et al., 2014), little is
known about ABCG1 function in cancer. Like ABCG2, ABCG1
is a member of a large superfamily of membrane-bound ABC-
containing proteins important for cellular transport (Tarling and
Edwards, 2011; Wang et al., 2004), where it mainly directs lipid
transport (Kennedy et al., 2005; Klucken et al., 2000). However,
ABCG2 was not highly expressed in o-GSCs as it is in high-
grade GSCs (Figure S4E), consistent with an absence of a
side population following Hoechst 33342 flow cytometry (data
not shown). Whereas the classification of glioma stem cells
based on ABCG2 expression is currently controversial (Gole-
biewska et al., 2013), the isolation of human low-grade GSCs us-
ing Hoechst-33342-mediated flow cytometry would likely be
unsuccessful.
Previous studies have suggested that downregulation of
ABCG1 can induce apoptosis in other cell types (Tarling et al.,
2010; Yvan-Charvet et al., 2010), perhaps in response to intra-
cellular lipid accumulation and subsequent ER stress (Tarling
and Edwards, 2011; Wojcik et al., 2008; Xue et al., 2013; Yvan-
Charvet et al., 2007). In this report, we demonstrate that
Abcg1 knockdown increased ER stress protein expression and
apoptosis, which could be rescued by PBA treatment. The adap-
tion to the ER stress is one critical mechanism for promoting
tumor cell growth and survival. In this regard, tumor cells use
adaptive pathways to circumvent the cellular stress conditions
associated with hypoxia, low glucose levels, or chemothera-
peutic drug exposure (Li and Lee, 2006; Luo and Lee, 2013).
As such, strategies aimed at blocking these adaptations may
improve treatment efficacy (Booth et al., 2014; Cho et al.,
2014; Ciechomska et al., 2013; Johnson et al., 2014; Liu et al.,
2013; Suzuki et al., 2013). Whereas the precise mechanism
responsible for ABCG1-mediated suppression of ER stress
remains to be elucidated, its potential importance to glioma(J) Expression of BiP, CHOP, cleaved-caspase-3, and cleaved-PARP was decre
stress inhibitor.
(K) Proposed mechanism underlying Abcg1 maintenance of o-GSC survival thro
Error bars denote mean ± SD. NS, not significant. *p < 0.01.
Cellbiology is underscored by preliminary studies demonstrating
that high ABCG1 expression correlated with shorter overall
survival in patients with glioblastoma of the mesenchymal sub-
type (J. Luo, personal communication). Further investigation of
ABCG1-mediated ER stress suppression in cancer could lead
to the development of new therapeutic approaches targeted
against gliomas characterized by increased Abcg1 expression.
In summary, we have successfully leveraged Nf1 GEM strains
to identify and characterize a previously difficult-to-study popu-
lation of CSCs from LGG. This strategy not only revealed differ-
ential drug sensitivities relevant to future therapeutic targeting
efforts but also highlighted the critical role of Abcg1 for o-GSC
survival through the suppression of ER stress.
EXPERIMENTAL PROCEDURES
Mice
All strains were generated (Supplemental Experimental Procedures), main-
tained on a C57BL/6 background, and used in accordance with an approved
Animal Studies protocol at Washington University. Athymic (B6.Cg/NTac-
Foxn1nu NE10) mice were purchased from Taconic Laboratories.
Primary NSC Isolation and Culture
Optic chiasm was microdissected from 3-month-old Nf1flox/flox, Nf1+/, and
Nf1+/GFAPCKO mice to generate primary optic nerve neurospheres. TVZ
NSCs were established from the third ventricle of 3-month-old Nf1flox/flox and
Nf1+/mice. NSC cultures and proliferation assays were performed as previ-
ously described (Lee et al., 2010). Wild-type and Nf1/ NSCs were gener-
ated from Nf1flox/flox mouse brains following infection with Ad5-LacZ and
Ad5-Cre adenovirus (University of Iowa Gene Transfer Core), respectively.
Loss of neurofibromin protein was confirmed by western blotting. All in vitro
experimentswere performed at least three times using primary NSC generated
using mice from different litters and independently transduced with the
respective constructs (Table S3).
Human Tumor Spheres
Human PA and GBM specimens were obtained from the Children’s Discov-
ery Institute Tumor Bank at the Washington University School of Medicine
and used under an approved Human Studies Protocol. Fresh human tumor
specimens were minced into small pieces and dissociated in Accutase at
37C. Single cells were obtained and cultured in tumor sphere media
(TSM) containing Neurobasal-A media supplemented with Glutamax, EGF
(20 ng/ml), FGF (20 ng/ml), leukemia inhibitory factor (20 ng/ml), N2, B-
27, and heparin (20 ng/ml). Additional human PA and GBM paraffin sections
were used from available clinical materials under an approved Human
Studies Protocol.
Multi-lineage Differentiation
Neurospheres were trypsinized and plated onto 24-well plates coated with
poly-D-lysine (50 mg/ml) and fibronectin (10 mg/ml) in defined NSC medium
containing N2, B27, and 1%FBSwithout growth factors. After 6 days, the cells
were fixed with 4% paraformaldehyde and stained with antibodies against
Tuj-1 (neuron), O4 (oligodendrocyte), and GFAP (astrocyte). The primary anti-
bodies used are listed in Table S4.
Lentivirus Infections
Abcg1 shRNA or control shGFP-containing pLKO.1 plasmid was co-trans-
fected with pMDLg/pRRE, pRSV-REV, and pCMV-VSV-G into HEK293T cells
using the FuGENEHD transfection reagent (Roche). o-GSCs were dissociatedased following Abcg1 knockdown in o-GSCs treated with PBA (2 mM), an ER
ugh suppression of ER stress.
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into single cells by trypsin and transduced with viral supernatants from
HEK293T cells. The knockdown efficiency of the Abcg1 shRNA constructs
was evaluated by western blotting.
Western Blotting
Western blotting was performed as previously reported (Lee et al., 2010) using
the primary antibodies listed in Table S4.
Intracranial Injections
Injections were performed as previously described (Kaul et al., 2012). 2.5- to
3-week-old Nf1+/ and athymic (nu/nu) mice were used for these experiments.
o-GSCswere implanted intracranially into the rightsidebrainstemusingastereo-
tactic device (coordinates = posterior 4.8 mm from the bregma, lateral 0.7 mm
[right], and depth 4.5 from dura mater). Mice were euthanized 6 months later.
Immunostaining
Paraffin or frozen sections were processed (Dasgupta and Gutmann, 2005)
prior to staining with appropriate antibodies (Table S4).
Microarray Analysis
Mouse optic glioma neurospheres, Nf1/ TVZ NSCs (TVZ_Cre), and wild-
type TVZ NSCs (TVZ_LacZ) RNA were subjected to Affymetrix GeneChip
MouseGenome 430 2.0 Array hybridization and the resulting data analyzed us-
ing Partex Genomics Suite Version 6.6 beta.
Real-Time qRT-PCR
Real-time qRT-PCR was performed as previously described (Yeh et al., 2009)
using the primers listed in Table S5. For each gene, the DDCT values were
calculated for each gene. H3f3a was used as an internal control.
Statistical Analysis
Each experiment was performed with samples from at least three indepen-
dent groups. Statistical significance was set at p < 0.05 using the Student’s
t test.
ACCESSION NUMBERS
Microarray analysis data have been deposited to the NCBI GEO and are avail-
able under accession number GSE58260.
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